Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

Hepatology

Volumn 64, Issue 4, 2016, Pages 1049-1056

  Abergel, Armand ^a   Metivier, Sophie ^b   Samuel, Didier ^c   Jiang, Deyuan ^d   Kersey, Kathryn ^d   Pang, Phillip S ^d   Svarovskaia, Evguenia ^d   Knox, Steven J ^d   Loustaud Ratti, Veronique ^e   Asselah, Tarik ^f  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b CHU PURPAN   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d GILEAD SCIENCES   (United States)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; GLUCOSE; HEMOGLOBIN; LEDIPASVIR; POTASSIUM; SODIUM; SOFOSBUVIR; TRIACYLGLYCEROL LIPASE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ALBUMIN BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; ASTHENIA; BACKACHE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIMIT OF QUANTITATION; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VERTIGO; WOUND; CLASSIFICATION; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; SOFOSBUVIR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84979740720     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28706     Document Type: Article

References (32)

1. Gower E, Estes CC, Hindman S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol 2014;61(1 Suppl):S45–S57.
2. Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, et al. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat 2013;20:294–296.
3. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007;14:460–467.
4. Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012;56:527–532.
5. Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, et al. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother 2015;59:6807–6815.
6. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30:342–355.
7. Asselah T, Bourliere M. Hepatitis C virus: Current and evolving treatments for genotype 4. Gastroenterol Clin North Am 2015;44:859–870.
8. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014;39:478–487.
9. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015;61:56–65.
10. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–1887.
11. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100–2107.
12. Wehmeyer MH, Jordan S, Lüth S, Hartl J, Stoehr A, Eißing C, et al. Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection. Dig Liver Dis 2015;47:811–814.
13. Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015;63:581–585.
14. Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015;62:1040–1046.
15. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012;57:24–31.
16. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–1898.
17. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–1493.
18. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–1888.
19. Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 2015;15:1049–1054.
20. Hézode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, et al.; COMMAND-4 study team. Randomized controlled trial of the NS5A inhibitor daclatasvir plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther (Lond) 2015;21:195–205.
21. Asselah T. Optimism for patients with genotype 4 HCV infection: Clinical trials with direct-acting antivirals finally available. J Hepatol 2015;62:996–999.
22. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015;64:948–956.
23. Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, Ledinghen V de, et al. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol 2015;63:30–37.
24. Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol 2015;62:1204–1206.
25. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015;385:2502–2509.
26. Asselah T, Hassanein TI, Qaqish RB, Feld JJ, Hezode C, Zeuzem, Stefan, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (AGATE-I). Hepatology 2015;62:563A.
27. Zeuzem, S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, et al. Grazoprevir- elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. Ann Intern Med 2015;163:1–13.
28. Asselah T, Reesink HW, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, et al. High efficacy of grazoprevir and elbasvir with or without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: a pooled analysis. Hepatology 2015;62:340A.
29. Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Doss W, et al. Ombitasvir/paritaprevir/ritonavir with ribavirin achieves high sustained virologic response (SVR) rates in Egyptian adults with chronic HCV genotype 4 infection. J Hepatol 2016;64:S772.
30. El Raziky M, Gamil M, Hammad R, Saad Hashem M, Khairy M, Elsharkawy A, et al. Treatment of hepatitis C genotype 4 patients with simeprevir and sofosbuvir: Preliminary results form a phase IIa, partially randomized, open-label trial conducted in Egypt (OSIRIS). Hepatology 2015;62:784A.
31. Esmat G, El Raziky M, Gomaa A, Elbaz T, Abouelkhair M, Sabry A, et al. Final results of the PYRAMID 1 study, a phase 3 registrational trial of ravidasvir (PPI-668) and sofosbuvir in HCV genoitype-4 patients: high rates of sustained viral clearance in cirrhotic and non-cirrhotic patients. J Hepatol 2016;64:S770.
32. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599–2607.